1 week Ago By Defense World Staff
Invesco Ltd. reduced its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) by 74.
0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 240,446 shares of the company’s stock after selling 683,699 shares during the quarter. Invesco Ltd.
owned about 0.52% of Pacira BioSciences worth $4,530,000 at the end of the most recent quarter. A number of other institutional investors have also recently modified their holdings of the business.
ExodusPoint Capital Management LP boosted its position in shares of Pacira BioSciences by 232.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 212,824 shares of the company’s stock worth $4,010,000 after purchasing an additional 148,842 shares in the last quarter.
Norges Bank acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $2,405,000. Charles Schwab Investment Management Inc. boosted its holdings in Pacira BioSciences by 16.
3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock worth $9,462,000 after buying an additional 70,307 shares in the last quarter.
Impax Asset Management Group plc grew its position in Pacira BioSciences by 14.8% during the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company’s stock worth $10,174,000 after buying an additional 69,424 shares during the period.
Finally, Wealthfront Advisers LLC purchased a new position in Pacira BioSciences in the fourth quarter valued at about $1,001,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.
Pacira BioSciences Stock PerformanceShares of NASDAQ PCRX opened at $25.72 on Friday. The company has a 50-day simple moving average of $24.
50 and a 200-day simple moving average of $21.49. The company has a debt-to-equity ratio of 0.
51, a current ratio of 2.25 and a quick ratio of 1.89.
The company has a market cap of $1.19 billion, a PE ratio of -12.67 and a beta of 0.
71. Pacira BioSciences, Inc. has a 12 month low of $11.
16 and a 12 month high of $31.67. Wall Street Analyst Weigh InSeveral equities research analysts have recently commented on PCRX shares.
Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright upped their target price on Pacira BioSciences from $48.
00 to $65.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price target for the stock from $8.
00 to $25.00 in a research note on Thursday, January 30th. Barclays increased their price objective on shares of Pacira BioSciences from $17.
00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $32.
00 target price on shares of Pacira BioSciences in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.
com, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $26.67.View Our Latest Research Report on PCRXPacira BioSciences Profile (Free Report)Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway.
Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Further ReadingFive stocks we like better than Pacira BioSciencesStock Analyst Ratings and Canadian Analyst RatingsMarkets Think Robinhood Earnings Could Send the Stock UpHigh Flyers: 3 Natural Gas Stocks for March 2022Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?What is a Dividend King? AT&T: Subscriber Growth & Buybacks Signal Bullish TurnaroundWant to see what other hedge funds are holding PCRX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report)..
